← Oncology Approval Tracker

FDA DECISION ·

Emrelis

telisotuzumab vedotin-tllv · AbbVie

Accelerated approvalNew therapyNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with previously systemically treated, locally advanced or metastatic nonsquamous NSCLC and high c-Met protein overexpression by an FDA-approved test (strong 3+ staining in at least 50% of tumor cells).

LAMPGEN ANALYSIS

Why it matters

This c-Met-directed antibody–drug conjugate is selected by protein expression, a different biomarker from MET exon 14 skipping.

What research teams should watch

Train pathology and screening teams on the exact staining threshold and collect the assay report rather than relying on a generic MET result.

PRIMARY RECORDS

Sources